3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Thyroid Nodule
2
Pain
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Agnosia
2
Prostatic Neoplasms
1
Neuroma
1
Neuralgia
1
Neoplasm Metastasis
1
Myoma
1
Multiple Pulmonary Nodules
1
Multiple Advanced Tumors After PD-1 Therapy Failure
1
Menorrhagia
1
Lymphoma, Follicular
1
Lipoma
1
Leiomyoma
1
Hypesthesia
1
Hyperthyroidism
1
Hyperaldosteronism
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Cicatrix
1
Carcinoma, Renal Cell
1
Breast Cancer Female
1
Bone Cancer Metastatic
1
Barrett Esophagus
1
Adenocarcinoma Of Esophagus
1
Adenocarcinoma
1
ACTH Syndrome, Ectopic
1
Interventions
lutetium Lu 177 dotatate
20
Magnetic Resonance Spectroscopy
10
pembrolizumab
9
Specimen Handling
7
Everolimus
7
cabozantinib
6
Nivolumab
6
lenvatinib
5
177Lu-octreotide, DOTA(0)-Tyr(3)-
5
surufatinib
4
amino-acid, glucose, and electrolyte solution
4
Capecitabine
4
olaparib
3
lanreotide
3
atezolizumab
3
Temozolomide
3
Octreotide
3
Lutetium-177
3
Ipilimumab
3
Injections
3
Fluorodeoxyglucose F18
3
Cyclophosphamide
3
gallium Ga 68 dotatate
2
fludarabine phosphate
2
fludarabine
2
avelumab
2
X-Rays
2
Radiotherapy
2
Phantoms, Imaging
2
PM 01183
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
Radiofrequency Ablation
×
1 year
×
Clear all
No trials found.